Surgical Endoscopy And Other Interventional Techniques

, Volume 20, Issue 9, pp 1364–1367 | Cite as

Proton pump inhibitors reduce gallbladder function

  • M. A. Cahan
  • L. Balduf
  • K. Colton
  • B. Palacioz
  • W. McCartney
  • T. M. FarrellEmail author



In the authors’ previous study of gallbladder function before and after fundoplication, 58% of the patients demonstrated preoperative gallbladder motor dysfunction, and 86% of those retested after operation and cessation of proton pump inhibitors (PPIs) normalized. Because no study has directly assessed the impact of antisecretory agents on gallbladder function, this study measured gallbladder ejection fraction (GBEF) in healthy volunteers before and after initiation of PPIs.


A total of 19 subjects completed the study, which included baseline determination of GBEF by cholecystokinin-stimulated hepatobiliary acid scan, 30 days of antisecretory therapy with omeprazole (40 mg daily), and repeat GBEF on day 30. Subjects were surveyed regarding compliance and symptoms.


For 15 of 19 subjects, PPI therapy was associated with reduced gallbladder motility. Evolution of symptoms consistent with a biliary etiology was reported by 26.7% of these subjects.


Short-term PPI therapy reduces gallbladder motility in healthy volunteers. Chronic PPI therapy may pose a risk for long-term gallbladder dysfunction and biliary complications.


Biliary dyskinesia Gallbladder ejection fraction Gastrin GERD Proton pump inhibitors 


  1. 1.
    Avidan B, Sonnenberg A, Schnell TG, Sontag SJ (2001) No association between gallstones and gastroesophageal reflux disease. Am J Gastroenterol 96: 2858–2862PubMedCrossRefGoogle Scholar
  2. 2.
    Bardhan KD (1999) Pantoprazole: a new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today (Barc) 35: 773–808Google Scholar
  3. 3.
    Bucceri AM, Calogero AE, Brogna A (2002) Gallbladder and gastric emptying: relationship to cholecystokininemia in diabetics. Eur J Intern Med 13: 123–128PubMedCrossRefGoogle Scholar
  4. 4.
    Cadiot G, Vissuzaine C, Pospai D, Ruszniewski P, Potet F, Mignon M (1995) Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa: preliminary results. Gastroenterol Clin Biol 19: 811–817PubMedGoogle Scholar
  5. 5.
    Capron JP, Payenneville H, Dumont M, Dupas JL, Lorriaux A (1978) Evidence for an association between cholelithiasis and hiatus hernia. Lancet 2: 329–331PubMedGoogle Scholar
  6. 6.
    Cattey RP, Wilson SD (1989) Cholelithiasis follows total gastrectomy in Zollinger-Ellison syndrome. Surgery 106: 1070–1073PubMedGoogle Scholar
  7. 7.
    Chowdhury JR, Berkowitz JM, Praissman M, Fara JW (1975) Interaction between octapeptide-cholecystokinin, gastrin, and secretin on cat gallbladder in vitro. Am J Physiol; 229: 1311–1315PubMedGoogle Scholar
  8. 8.
    Chowdhury JR, Berkowitz JM, Praissman M, Fara JW (1976) Effect of sulfated and nonsulfated gastrin and octapeptide-cholecystokinin on cat gall bladder in vitro. Experientia 32: 1173–1175PubMedCrossRefGoogle Scholar
  9. 9.
    DiBaise JK, Oleynikov D (2003) Does gallbladder ejection fraction predict outcome after cholecystectomy for suspected chronic acalculous gallbladder dysfunction? A systematic review. Am J Gastroenterol 98: 2605–2611PubMedCrossRefGoogle Scholar
  10. 10.
    Festen HP, Thijs JC, Lamers CB, Jansen JM, Pals G, Frants RR, Defize J, Meuwissen SG (1984) Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology 87: 1030–1034PubMedGoogle Scholar
  11. 11.
    Gallup Organization (1988) A Gallup Organization National Survey: Heartburn Across America. Gallup Organization, Princeton, NJGoogle Scholar
  12. 12.
    Grider JR, Makhlouf GM (1990) Distinct receptors for cholecystokinin and gastrin on muscle cells of stomach and gallbladder. Am J Physiol 259: G184–G190PubMedGoogle Scholar
  13. 13.
    Koop H, Klein M, Arnold R (1990) Serum gastrin levels during long-term omeprazole treatment. Aliment Pharm Ther 4: 131–138CrossRefGoogle Scholar
  14. 14.
    Krishnamurthy GT, Krishnamurthy S, Brown PH (2004) Constancy and variability of gallbladder ejection fraction: impact on diagnosis and therapy. J Nucl Med 45: 1872–1877PubMedGoogle Scholar
  15. 15.
    Krishnamurthy S, Krishnamurthy GT (1997) Biliary dyskinesia: role of the sphincter of Oddi, gallbladder, and cholecystokinin. J Nucl Med 38: 1824–1830PubMedGoogle Scholar
  16. 16.
    Manifold DK, Anggiansah A, Owen WJ (2000) Effect of cholecystectomy on gastroesophageal and duodenogastric reflux. Am J Gastroenterol 95: 2746–2750PubMedGoogle Scholar
  17. 17.
    Morton JM, Bowers SP, Lucktong TA, Mattar S, Bradshaw WA, Behrns KE, Koruda MJ, Herbst CA, McCartney W, Halkar RK, Smith CD, Farrell TM (2002) Gallbladder function before and after fundoplication. J Gastrointest Surg 6: 806–810PubMedCrossRefGoogle Scholar
  18. 18.
    Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H (2004) Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with Helicobacter pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI. Hepatogastroenterology 51: 338–342PubMedGoogle Scholar
  19. 19.
    Portincasa P, Di Ciaula A, Palmieri V, Velardi A, VanBerge-Henegouwen GP, Palasciano G (1997) Impaired gallbladder and gastric motility and pathological gastro-oesophageal reflux in gallstone patients. Eur J Clin Invest 27: 653–661PubMedCrossRefGoogle Scholar
  20. 20.
    Rasmussen L, Oster-Jorgensen E, Qvist N, Hovendal CP, Kraglund K, Olsen O, Schaffalitzky de Muckadell OB, Rehfeld J, Pedersen SA (1992) The effects of omeprazole on interdigestive motility and early postprandial levels of gastrin and secretin. Scan J Gastroenterol 27: 119–123CrossRefGoogle Scholar
  21. 21.
    Rasmussen L, Qvist N, Oster-Jorgensen E, Rehfeld JF, Holst JJ, Pedersen SA (1997) A double-blind placebo-controlled study of the effects of omeprazole on gut hormone secretion and gastric emptying rate. Scand J Gastroenterol 32: 900–905PubMedGoogle Scholar
  22. 22.
    Ryan J, Cohen S (1976) Gallbladder pressure–volume response to gastrointestinal hormones. Am J Physiol 230: 1461–1465PubMedGoogle Scholar
  23. 23.
    Schjoldager BT (1994) Role of CCK in gallbladder function. Ann NY Acad Sci 713: 207–218PubMedGoogle Scholar
  24. 24.
    Toouli J, Hogan WJ, Geenen JE, Dodds WJ, Arndorfer RC (1982) Action of cholecystokinin octapeptide on sphincter of Oddi basal pressure and phasic wave activity in humans. Surgery 92: 497–503PubMedGoogle Scholar
  25. 25.
    Vaczek D (2003) Top 200 drugs of 2002. Pharm Times, April p 20Google Scholar
  26. 26.
    Valenzuela JE, Walsh JH, Isenberg JI (1976) Effect of gastrin on pancreatic enzyme secretion and gallbladder emptying in man. Gastroenterology 71: 409–411PubMedGoogle Scholar
  27. 27.
    Watson S, Arkinstall S (1994) Cholecystokinin (CCK) and gastrin. In: Watson S, Arkinstall S (eds) The G Protein-Linked Receptor Factsbook. Academic Press, London pp 89–95Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • M. A. Cahan
    • 1
  • L. Balduf
    • 1
  • K. Colton
    • 1
  • B. Palacioz
    • 1
  • W. McCartney
    • 2
  • T. M. Farrell
    • 1
    Email author
  1. 1.Department of SurgeryUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaUSA
  2. 2.Department of RadiologyUniversity of North Carolina at Chapel HillNorth CarolinaUSA

Personalised recommendations